Dr. Frangioni is a pioneer in the field of zwitterionicity, having led the field of background reduction as it relates to cancer imaging and treatment for nearly 30 years. Previously board certified in internal medicine and medical oncology, Dr. Frangioni served as Professor of Medicine and Professor of Radiology at Harvard Medical School before leaving in 2014 to found Curadel. He has published over 220 peer-reviewed papers resulting in over 27,000 citations. Dr. Frangioni is also the recipient of over $60M of grant funding from the National Institutes of Health, Department of Energy, and multiple other funding agencies.
Dr. Frangioni studied Engineering Sciences at Harvard College, earned his medical degree from Harvard Medical School in the Harvard-MIT Division of Health Sciences & Technology (HST), and earned his doctorate from the Department of Cellular & Molecular Physiology at the Harvard Graduate School of Arts and Sciences. His internship and residency was at Brigham & Women’s Hospital and his medical oncology fellowship was at Beth Israel Deaconess Medical Center in Boston.